VYCO · Vycor Medical, Inc.

Vycor Medical achieved profitability on an operating basis for Q1 2026, reporting GAAP operating income of $45,808 compared to a loss of $12,806 in the prior year period, primarily driven by a 5% revenue increase to $458,540. The Vycor Medical division, which accounts for the bulk of revenue at $440,441, saw growth mainly from international markets, aligning with the company's strategic focus. Gross margins remained stable at 82%, reflecting consistent pricing and cost efficiency. NovaVision contributed modestly with $18,099 in revenue and a 89% gross margin. Non-GAAP cash operating expenses decreased to $315,365 from $338,146, excluding non-cash depreciation of $13,980 and prior stock compensation, resulting in non-GAAP operating profit of $59,788, up significantly from $20,388. Despite operating gains, net loss to common stockholders was $142,077 after preferred dividends of $162,185, though improved from the prior year's larger loss. Two new peer-reviewed studies bolstered the ViewSite Brain Access System's clinical validation, highlighting reduced neurological deficits versus traditional methods and effective integration with neuro-navigation, potentially supporting future adoption in neurosurgery.